27663860|t|Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension.
27663860|a|The aim of this study was to investigate the in vivo role of angiotensin II type 1a (AT1a) receptor in renal damage as a result of hypertension by using transgenic mice with AT1a receptor gene disruption. Transgenic mice that express human liver-type fatty acid binding protein (L-FABP) with or without disruption of the AT1a receptor gene (L-FABP(+/-) AT1a(-/-), and L-FABP(+/-) AT1a(+/+), respectively) were used with urinary L-FABP as an indicator of tubulointerstitial damage. Those female mice were administered subcutaneously deoxycorticosterone acetate (DOCA)-salt tablets plus drinking water that contained 1% saline for 28 d after uninephrectomy. In L-FABP(+/-) AT1a(+/+) mice that received DOCA-salt treatment, hypertension was induced and slight expansion of glomerular area, glomerular sclerosis, and tubulointerstitial damage were observed. In L-FABP(+/-) AT1a(-/-) mice that received DOCA-salt treatment, hypertension was similarly induced and the degree of glomerular damage was significantly more severe than in L-FABP(+/-) AT1a(+/+)-DOCA mice. Urinary L-FABP levels were significantly higher in L-FABP(+/-) AT1a(-/-)-DOCA mice compared with those in L-FABP(+/-) AT1a(+/+)-DOCA mice. Hydralazine treatment significantly attenuated renal damage that was found in L-FABP(+/-) AT1a(-/-)-DOCA mice along with a reduction in blood pressure. In summary, activation of the AT1a receptor may contribute to maintenance of the glomerular structure against hypertensive renal damage.-Hisamichi, M., Kamijo-Ikemori, A., Sugaya, T., Ichikawa, D., Natsuki, T., Hoshino, S., Kimura, K., Shibagaki, Y. Role of angiotensin II type 1a receptor in renal injury induced by deoxycorticosterone acetate-salt hypertension.
27663860	8	39	angiotensin II type 1a receptor	GeneOrGeneProduct	11607
27663860	43	55	renal injury	DiseaseOrPhenotypicFeature	D007674
27663860	67	94	deoxycorticosterone acetate	ChemicalEntity	D064791
27663860	100	112	hypertension	DiseaseOrPhenotypicFeature	D006973
27663860	175	213	angiotensin II type 1a (AT1a) receptor	GeneOrGeneProduct	11607
27663860	217	229	renal damage	DiseaseOrPhenotypicFeature	D007674
27663860	245	257	hypertension	DiseaseOrPhenotypicFeature	D006973
27663860	278	282	mice	OrganismTaxon	10090
27663860	288	301	AT1a receptor	GeneOrGeneProduct	11607
27663860	330	334	mice	OrganismTaxon	10090
27663860	348	353	human	OrganismTaxon	9606
27663860	354	391	liver-type fatty acid binding protein	GeneOrGeneProduct	2168
27663860	393	399	L-FABP	GeneOrGeneProduct	2168
27663860	435	448	AT1a receptor	GeneOrGeneProduct	11607
27663860	455	461	L-FABP	GeneOrGeneProduct	2168
27663860	467	471	AT1a	GeneOrGeneProduct	11607
27663860	482	488	L-FABP	GeneOrGeneProduct	2168
27663860	494	498	AT1a	GeneOrGeneProduct	11607
27663860	542	548	L-FABP	GeneOrGeneProduct	2168
27663860	568	593	tubulointerstitial damage	DiseaseOrPhenotypicFeature	D007674
27663860	608	612	mice	OrganismTaxon	10090
27663860	646	673	deoxycorticosterone acetate	ChemicalEntity	D064791
27663860	675	679	DOCA	ChemicalEntity	D064791
27663860	773	779	L-FABP	GeneOrGeneProduct	2168
27663860	785	789	AT1a	GeneOrGeneProduct	11607
27663860	795	799	mice	OrganismTaxon	10090
27663860	814	818	DOCA	ChemicalEntity	D064791
27663860	835	847	hypertension	DiseaseOrPhenotypicFeature	D006973
27663860	901	921	glomerular sclerosis	DiseaseOrPhenotypicFeature	D007674
27663860	927	952	tubulointerstitial damage	DiseaseOrPhenotypicFeature	D007674
27663860	971	977	L-FABP	GeneOrGeneProduct	2168
27663860	983	987	AT1a	GeneOrGeneProduct	11607
27663860	993	997	mice	OrganismTaxon	10090
27663860	1012	1016	DOCA	ChemicalEntity	D064791
27663860	1033	1045	hypertension	DiseaseOrPhenotypicFeature	D006973
27663860	1086	1103	glomerular damage	DiseaseOrPhenotypicFeature	D007674
27663860	1142	1148	L-FABP	GeneOrGeneProduct	2168
27663860	1154	1158	AT1a	GeneOrGeneProduct	11607
27663860	1164	1168	DOCA	ChemicalEntity	D064791
27663860	1169	1173	mice	OrganismTaxon	10090
27663860	1183	1189	L-FABP	GeneOrGeneProduct	2168
27663860	1226	1232	L-FABP	GeneOrGeneProduct	2168
27663860	1238	1242	AT1a	GeneOrGeneProduct	11607
27663860	1248	1252	DOCA	ChemicalEntity	D064791
27663860	1253	1257	mice	OrganismTaxon	10090
27663860	1281	1287	L-FABP	GeneOrGeneProduct	2168
27663860	1293	1297	AT1a	GeneOrGeneProduct	11607
27663860	1303	1307	DOCA	ChemicalEntity	D064791
27663860	1308	1312	mice	OrganismTaxon	10090
27663860	1314	1325	Hydralazine	ChemicalEntity	D006830
27663860	1361	1373	renal damage	DiseaseOrPhenotypicFeature	D007674
27663860	1392	1398	L-FABP	GeneOrGeneProduct	2168
27663860	1404	1408	AT1a	GeneOrGeneProduct	11607
27663860	1414	1418	DOCA	ChemicalEntity	D064791
27663860	1419	1423	mice	OrganismTaxon	10090
27663860	1496	1509	AT1a receptor	GeneOrGeneProduct	11607
27663860	1576	1601	hypertensive renal damage	DiseaseOrPhenotypicFeature	D006973,D007674
27663860	1724	1755	angiotensin II type 1a receptor	GeneOrGeneProduct	11607
27663860	1759	1771	renal injury	DiseaseOrPhenotypicFeature	D007674
27663860	1783	1810	deoxycorticosterone acetate	ChemicalEntity	D064791
27663860	1816	1828	hypertension	DiseaseOrPhenotypicFeature	D006973
27663860	Negative_Correlation	D006830	D007674	No
27663860	Negative_Correlation	2168	11607	Novel
27663860	Association	2168	D007674	No
27663860	Association	11607	D007674	Novel
27663860	Association	D064791	2168	No
27663860	Association	D064791	11607	Novel
27663860	Positive_Correlation	D064791	D006973	No
27663860	Positive_Correlation	D007674	D064791	No